42 related articles for article (PubMed ID: 35916904)
1. Oral Anticancer Agent (OAA) Adherence and Survival in Elderly Patients With Metastatic Renal Cell Carcinoma (mRCC).
Dinan MA; Wilson LE; Greiner MA; Spees LP; Pritchard JE; Zhang T; Kaye D; George D; Scales CD; Baggett CD; Gross CP; Leapman MS; Wheeler SB
Urology; 2022 Oct; 168():129-136. PubMed ID: 35878815
[TBL] [Abstract][Full Text] [Related]
2. Overall survival in renal cell carcinoma after introduction of targeted therapies: a Norwegian population-based study.
Beisland C; Johannesen TB; Klepp O; Axcrona U; Torgersen KM; Kowalski J; Solli O; Sandin R; Oldenburg J
Onco Targets Ther; 2017; 10():371-385. PubMed ID: 28144152
[TBL] [Abstract][Full Text] [Related]
3. Management of metastatic renal cell carcinoma - mini review.
Bharthuar A; Pandey H; Sood S
J Kidney Cancer VHL; 2015; 2(2):75-83. PubMed ID: 28326262
[TBL] [Abstract][Full Text] [Related]
4. The 5th Kidney Cancer Research Summit: Research Accelerating Cures for Renal Cell Carcinoma in 2023.
Choueiri TK; Pal SK; Lewis B; Poteat S; Pels K; Hammers H
Oncologist; 2024 Feb; 29(2):91-98. PubMed ID: 38048064
[TBL] [Abstract][Full Text] [Related]
5. Association of lncRNA and transcriptome intersections with response to targeted therapy in metastatic renal cell carcinoma.
Tesarova T; Koucka K; Vaclavikova R; Seborova K; Hora M; Hes O; Pivovarcikova K; Soucek P; Fiala O
Oncol Lett; 2023 Sep; 26(3):365. PubMed ID: 37559591
[TBL] [Abstract][Full Text] [Related]
6. The Efficacy and Safety of Immune Checkpoint Inhibitor and Tyrosine Kinase Inhibitor Combination Therapy for Advanced or Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Real-World Cohort Study.
Iinuma K; Yamada T; Kameyama K; Taniguchi T; Kawada K; Ishida T; Nagai S; Enomoto T; Ueda S; Takagi K; Kawase M; Takeuchi S; Kawase K; Kato D; Takai M; Nakane K; Koie T
Cancers (Basel); 2023 Feb; 15(3):. PubMed ID: 36765903
[TBL] [Abstract][Full Text] [Related]
7. Impact of Clinicopathological Features on Survival in Patients Treated with First-line Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Renal Cell Carcinoma: A Meta-analysis of Randomized Clinical Trials.
Rizzo A; Mollica V; Santoni M; Ricci AD; Rosellini M; Marchetti A; Montironi R; Ardizzoni A; Massari F
Eur Urol Focus; 2022 Mar; 8(2):514-521. PubMed ID: 33714725
[TBL] [Abstract][Full Text] [Related]
8. Carcinoma of Unknown Primary Site (CUP) With Metastatic Renal-Cell Carcinoma (mRCC) Histologic and Immunohistochemical Characteristics (CUP-mRCC): Results From Consecutive Patients Treated With Targeted Therapy and Review of Literature.
Overby A; Duval L; Ladekarl M; Laursen BE; Donskov F
Clin Genitourin Cancer; 2019 Feb; 17(1):e32-e37. PubMed ID: 30268423
[TBL] [Abstract][Full Text] [Related]
9. Improving survival in metastatic renal cell carcinoma (mRCC) patients: do elderly patients benefit from expanded targeted therapeutic options?
Eggers H; Schünemann C; Grünwald V; Rudolph L; Tiemann ML; Reuter C; Anders-Meyn MF; Ganser A; Ivanyi P
World J Urol; 2022 Oct; 40(10):2489-2497. PubMed ID: 35916904
[TBL] [Abstract][Full Text] [Related]
10. Cabozantinib in the treatment of metastatic renal cell carcinoma - final data analysis from four oncology centers in the Czech Republic.
Richter I; Poprach A; Zemánková A; Büchler T; Bartoš J; Šámal V; Študentová H; Rozsypalová A; Dvořák J; Brom O; Melichar B
Klin Onkol; 2021; 34(5):392-400. PubMed ID: 34915708
[TBL] [Abstract][Full Text] [Related]
11. Outcomes of Patients With Metastatic Renal Cell Carcinoma and Bone Metastases in the Targeted Therapy Era.
Kalra S; Verma J; Atkinson BJ; Matin SF; Wood CG; Karam JA; Lin SH; Satcher RL; Tamboli P; Sircar K; Rao P; Corn PG; Tannir NM; Jonasch E
Clin Genitourin Cancer; 2017 Jun; 15(3):363-370. PubMed ID: 28216278
[TBL] [Abstract][Full Text] [Related]
12. Activity of single-agent bevacizumab in patients with metastatic renal cell carcinoma previously treated with vascular endothelial growth factor tyrosine kinase inhibitors.
Turnbull JD; Cobert J; Jaffe T; Harrison MR; George DJ; Armstrong AJ
Clin Genitourin Cancer; 2013 Mar; 11(1):45-50. PubMed ID: 23041453
[TBL] [Abstract][Full Text] [Related]
13. Treatment patterns and health outcomes in metastatic renal cell carcinoma patients treated with targeted systemic therapies in the UK.
Hawkins R; Fife K; Hurst M; Wang M; Naicker N; Nolasco S; Eisen T; Matakidou A; Gordon J
BMC Cancer; 2020 Jul; 20(1):670. PubMed ID: 32680483
[TBL] [Abstract][Full Text] [Related]
14. Significance of preoperative prognostic nutrition index as prognostic predictors in patients with metastatic renal cell carcinoma with tyrosine kinase inhibitors as first-line target therapy.
Cai W; Zhong H; Kong W; Dong B; Chen Y; Zhou L; Xue W; Huang Y; Zhang J; Huang J
Int Urol Nephrol; 2017 Nov; 49(11):1955-1963. PubMed ID: 28889323
[TBL] [Abstract][Full Text] [Related]
15. Association of Chemotherapy With Survival in Elderly Patients With Multiple Comorbidities and Estrogen Receptor-Positive, Node-Positive Breast Cancer.
Tamirisa N; Lin H; Shen Y; Shaitelman SF; Sri Karuturi M; Giordano SH; Babiera G; Bedrosian I
JAMA Oncol; 2020 Oct; 6(10):1548-1554. PubMed ID: 32672820
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]